

#18
7/11/03


ATTORNEY'S DOCKET NO. V00139.70063.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Newell et al.
Serial No.: 09/470,494
Filed: December 22, 1999
For: USE OF CD40 ENGAGEMENT TO ALTER T CELL RECEPTOR USAGE
Examiner: Phillip Gambel
Art Unit: 1644

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 5th day of June, 2003.


Helen C. Lockhart

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
JUN 12 2003
TECH CENTER 1600/2900

Response to Restriction Requirement

Sir:

In response to the Office Action dated February 3, 2003, Applicants hereby file the following response. Additionally, a request for a three-month extension of time is enclosed for the response.

Election

Applicants hereby elect CD86 as the co-stimulatory molecule of choice for initial examination on the merits. Applicants acknowledge that upon allowance of a generic claim, Applicants will be entitled to consideration of the claims to additional species which are written in dependent form or otherwise include all of the limitations of an allowed generic claim as provided by 37 C.F.R. §1.141.